295 related articles for article (PubMed ID: 25677770)
21. Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications.
Chiou LC; Liao YY; Fan PC; Kuo PH; Wang CH; Riemer C; Prinssen EP
Curr Drug Targets; 2007 Jan; 8(1):117-35. PubMed ID: 17266536
[TBL] [Abstract][Full Text] [Related]
22. Regulation of pancreatic secretion in vitro by nociceptin/orphanin FQ and opioid receptors: a comparative study.
Linari G; Agostini S; Broccardo M; Petrella C; Improta G
Pharmacol Res; 2006 Nov; 54(5):356-60. PubMed ID: 16979347
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological Profile of Nociceptin/Orphanin FQ Receptors Interacting with G-Proteins and β-Arrestins 2.
Malfacini D; Ambrosio C; Gro' MC; Sbraccia M; Trapella C; Guerrini R; Bonora M; Pinton P; Costa T; Calo' G
PLoS One; 2015; 10(8):e0132865. PubMed ID: 26248189
[TBL] [Abstract][Full Text] [Related]
24. Nociceptin/orphanin FQ peptide receptor antagonist JTC-801 reverses pain and anxiety symptoms in a rat model of post-traumatic stress disorder.
Zhang Y; Simpson-Durand CD; Standifer KM
Br J Pharmacol; 2015 Jan; 172(2):571-82. PubMed ID: 24666365
[TBL] [Abstract][Full Text] [Related]
25. Nociceptin/orphanin-FQ modulation of learning and memory.
Abdel-Mouttalib O
Vitam Horm; 2015; 97():323-45. PubMed ID: 25677778
[TBL] [Abstract][Full Text] [Related]
26. Cellular mechanisms of nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor regulation and heterologous regulation by N/OFQ.
Donica CL; Awwad HO; Thakker DR; Standifer KM
Mol Pharmacol; 2013 May; 83(5):907-18. PubMed ID: 23395957
[TBL] [Abstract][Full Text] [Related]
27. Characterisation of the Novel Mixed Mu-NOP Peptide Ligand Dermorphin-N/OFQ (DeNo).
Bird MF; Cerlesi MC; Brown M; Malfacini D; Vezzi V; Molinari P; Micheli L; Di Cesare Mannelli L; Ghelardini C; Guerrini R; Calò G; Lambert DG
PLoS One; 2016; 11(6):e0156897. PubMed ID: 27272042
[TBL] [Abstract][Full Text] [Related]
28. Activation of nociceptin/orphanin FQ receptors inhibits contextual fear memory reconsolidation.
Rekik K; Faria Da Silva R; Colom M; Pacifico S; Zaveri NT; Calo' G; Rampon C; Frances B; Mouledous L
Neuropharmacology; 2017 Oct; 125():39-49. PubMed ID: 28705439
[TBL] [Abstract][Full Text] [Related]
29. The design and synthesis of a novel quinolizidine template for potent opioid and opioid receptor-like (ORL1, NOP) receptor ligands.
Jong L; Zaveri N; Toll L
Bioorg Med Chem Lett; 2004 Jan; 14(1):181-5. PubMed ID: 14684324
[TBL] [Abstract][Full Text] [Related]
30. Acute and subchronic antinociceptive effects of nociceptin/orphanin FQ receptor agonists infused by intrathecal route in rats.
Micheli L; Di Cesare Mannelli L; Guerrini R; Trapella C; Zanardelli M; Ciccocioppo R; Rizzi A; Ghelardini C; Calò G
Eur J Pharmacol; 2015 May; 754():73-81. PubMed ID: 25704616
[TBL] [Abstract][Full Text] [Related]
31. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
[TBL] [Abstract][Full Text] [Related]
32. Structure-activity studies on high affinity NOP-active hexapeptides.
Judd AK; Tuttle DJ; Jones RW; Sanchez A; Polgar W; Berzetei-Gurske I; Toll L
J Pept Res; 2004 Sep; 64(3):87-94. PubMed ID: 15317498
[TBL] [Abstract][Full Text] [Related]
33. NOP Ligands for the Treatment of Anxiety and Mood Disorders.
Gavioli EC; Holanda VAD; Ruzza C
Handb Exp Pharmacol; 2019; 254():233-257. PubMed ID: 30535941
[TBL] [Abstract][Full Text] [Related]
34. [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor.
Calo G; Rizzi A; Rizzi D; Bigoni R; Guerrini R; Marzola G; Marti M; McDonald J; Morari M; Lambert DG; Salvadori S; Regoli D
Br J Pharmacol; 2002 May; 136(2):303-11. PubMed ID: 12010780
[TBL] [Abstract][Full Text] [Related]
35. Binding of the novel radioligand [(3)H]UFP-101 to recombinant human and native rat nociceptin/orphanin FQ receptors.
Ibba M; Kitayama M; McDonald J; Calo G; Guerrini R; Farkas J; Toth G; Lambert DG
Naunyn Schmiedebergs Arch Pharmacol; 2008 Dec; 378(6):553-61. PubMed ID: 18807245
[TBL] [Abstract][Full Text] [Related]
36. Synergistic interaction between the agonism of cebranopadol at nociceptin/orphanin FQ and classical opioid receptors in the rat spinal nerve ligation model.
Christoph T; Raffa R; De Vry J; Schröder W
Pharmacol Res Perspect; 2018 Dec; 6(6):e00444. PubMed ID: 30519474
[TBL] [Abstract][Full Text] [Related]
37. Spinal antinociceptive effects of the novel NOP receptor agonist PWT2-nociceptin/orphanin FQ in mice and monkeys.
Rizzi A; Sukhtankar DD; Ding H; Hayashida K; Ruzza C; Guerrini R; Calò G; Ko MC
Br J Pharmacol; 2015 Jul; 172(14):3661-70. PubMed ID: 25828800
[TBL] [Abstract][Full Text] [Related]
38. Effects of NOP-Related Ligands in Nonhuman Primates.
Kiguchi N; Ko MC
Handb Exp Pharmacol; 2019; 254():323-343. PubMed ID: 30879202
[TBL] [Abstract][Full Text] [Related]
39. Biochemical and pharmacological investigation of novel nociceptin/OFQ analogues and N/OFQ-RYYRIK hybrid peptides.
Erdei AI; Borbély A; Magyar A; Szűcs E; Ötvös F; Gombos D; Al-Khrasani M; Stefanucci A; Dimmito MP; Luisi G; Mollica A; Benyhe S
Peptides; 2019 Feb; 112():106-113. PubMed ID: 30513351
[TBL] [Abstract][Full Text] [Related]
40. [Dmt1]N/OFQ(1-13)-NH2: a potent nociceptin/orphanin FQ and opioid receptor universal agonist.
Molinari S; Camarda V; Rizzi A; Marzola G; Salvadori S; Marzola E; Molinari P; McDonald J; Ko MC; Lambert DG; Calo' G; Guerrini R
Br J Pharmacol; 2013 Jan; 168(1):151-62. PubMed ID: 22827708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
